Eidos Therapeutics closes $64mm Series B round
Executive Summary
Eidos Therapeutics Inc. raised $64mm in a Series B financing round led by RA Capital Management (adds board seat). The company's parent, BridgeBio Pharma, and new investors Janus Henderson, Viking Global Investors, Aisling Capital (adds board seat), Perceptive Advisors, Cormorant Asset Management, and Amzak Health Investors also participated.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice